INVESTOR ALERT: Investigation of Mereo BioPharma Group plc (MREO) by Holzer & Holzer, LLC

Group 1 - Holzer & Holzer, LLC is investigating Mereo BioPharma Group plc for potential compliance issues with federal securities laws following the announcement of Phase 3 study results for setrusumab, which did not achieve statistical significance against primary endpoints [1] - The Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta revealed that neither study met the primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement of the study results, Mereo's stock price experienced a decline [1]